Article
Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.
British journal of clinical pharmacology - 1 Apr 2006
Bernsdorf Annika, Giessmann Thomas, Modess Christiane, Wegner Danilo, Igelbrink Stefanie, Hecker Ute, Haenisch Sierk, Cascorbi Ingolf, Terhaag Bernd, Siegmund Werner
Abstract excerpt
AIMS: To evaluate whether simvastatin influences (i) the intestinal expression of P-glycoprotein (P-gp) and MRP2, and (ii) the disposition of the beta(1)-selective blocker talinolol, a substrate of these transporter proteins. METHODS: The disposition of talinolol after intravenous (30 mg) and single or repeated oral administration (100 mg daily) was monitored before and after chronic treatment with simvastatin...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.